Crohn's Disease in
the Clinical Setting
About CIMZIA®
Dosing and
Administration
Clinical Trials Overview
Patient Support
Safety Information
Resources
For Patients & Caregivers
Prescribing Information


This site is intended for
US residents.

Crohn's Disease Implications

The clinical course of Crohn's disease

The graph below illustrates the lifetime clinical course of Crohn's disease (CD), breaking it down by disease state.1

Five years after diagnosis:

  • The proportion of patients:
    • in medical remission decreases to about 30%
    • with mild disease increases to 35%
  • Only a small proportion of patients require surgery or are receiving corticosteroids or immunosuppressive medication
  • A high proportion of patients are in "postsurgery remission"

The development of complications

Most patients with high and chronic disease activity will develop a stricturing or penetrating (fistulizing) complication. This can impact hospitalization and surgical costs.2

The Kaplan-Meier chart below is from a retrospective study assessing the long-term disease progression of CD in more than 2000 patients. The graph illustrates the probability of patients remaining free of penetrating (upper curve), stricturing (middle), and inflammatory (lower curve) complications.2

The emotional cost to patients

The symptoms and complications of CD can greatly affect the quality of life of an individual, including physical and emotional well-being, social functioning, and self-image.3 In the Voices of Crohn's Survey, patients with Crohn's disease reported that the disease significantly impacts their personal and professional lives. In fact, 93% of Crohn's patients surveyed felt that the disease has an impact on their overall emotional well-being.4

Time to diagnosis

Patients with CD often wait more than 3 years before being properly diagnosed, often resulting in frustration to the patient. Additionally, 75% of patients felt that physicians and employers were in need of increased awareness about CD.4

References:

  1. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49-57.
  2. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250.
  3. Crohn's Disease and Ulcerative Colitis: Emotional Factors. Crohn's and Colitis Foundation of America. Available at: http://www.ccfa.org/frameviewer/?url=/media/pdf/emotional.pdf&LMI=2.1. Accessed November 30, 2008.
  4. Voices of Crohn's Key Findings. Available at:
    http://www.voicesofcrohns.com/voicesofcrohns/
    pages/voices/key_findings.jsp
    . Accessed November 30, 2008.

CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
For more information 1.866.4.CIMZIA
CIMZIA